Related Experiment Videos
CRIPak, a novel endogenous Pak1 inhibitor
A H Talukder1, Q Meng, R Kumar
1Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Oncogene
|November 10, 2005
Summary
Cysteine-rich inhibitor of Pak1 (CRIPak) is a newly discovered protein that negatively regulates p21-activated protein kinase 1 (Pak1). CRIPak inhibits Pak1 activity, impacting cell survival and estrogen receptor signaling in breast cancer.
Area of Science:
- Molecular Biology
- Cell Biology
- Cancer Research
Background:
- p21-activated protein kinase 1 (Pak1) is crucial for cell functions like cytoskeleton reorganization, cell survival, and estrogen receptor (ER) signaling.
- Deregulation of Pak1 is observed in various cancers, highlighting the need to understand its regulatory mechanisms.
- While Pak1 activators are known, negative regulators remain less understood.
Purpose of the Study:
- To identify and characterize novel negative regulators of Pak1.
- To investigate the interaction between CRIPak and Pak1.
- To determine the functional role of CRIPak in Pak1-mediated cellular processes, particularly ER transactivation.
Main Methods:
- Yeast two-hybrid screening of a mammary gland library to identify Pak1-interacting proteins.
- Gene localization and domain analysis of the identified protein.
- In vitro and in vivo kinase assays to assess Pak1 inhibition by CRIPak.
- Analysis of Pak1-mediated LIM kinase activation and ER transactivation.
- CRIPak inhibition studies to observe effects on Pak1 activity and cellular processes.
- Immunofluorescence to study CRIPak and ER colocalization.
Main Results:
- Cysteine-rich inhibitor of Pak1 (CRIPak) was identified as a novel Pak1-interacting protein.
- CRIPak, an intronless gene on chromosome 4p16.3, contains zinc-finger and cysteine-rich domains and is widely expressed.
- CRIPak directly binds to the N-terminal regulatory domain of Pak1 and inhibits its kinase activity.
- CRIPak suppresses Pak1-mediated LIM kinase activation and ER transactivation.
- Inhibition of endogenous CRIPak leads to increased Pak1 activity, cytoskeleton remodeling, and ER transactivation.
- Hormonal stimulation increases CRIPak expression and its nuclear colocalization with ER.
Conclusions:
- CRIPak is a novel negative regulator of Pak1 kinase activity.
- CRIPak plays a significant role in modulating Pak1-mediated ER transactivation in breast cancer cells.
- CRIPak represents a potential therapeutic target for cancers involving Pak1 dysregulation.